A novel specific immunoassay for plasma two-chain factor VIIa: Investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes

Blood

Volumn 89, Issue 3, 1997, Pages 767-775

  Philippou, Helen ^a   Adami, Antonella ^a   Amersey, Rajiv A ^a   Stubbs, Peter J ^a   Lane, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0030952227     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.767     Document Type: Article

References (24)

1. Broze GJ Jr: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46:103, 1995
2. Miller GJ Walter SJ Stirling Y Thompson SG Esnouf MP, Meade TW: Assay of factor VII activity by two techniques: Evidence for increased conversion of VII to alpha VIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol 59:249, 1985
3. Osterud B: How to measure factor VII and factor VII activation. Haemostasis 13:161, 1983
4. Genest JJ, Cohn JS: Clustering of cardiovascular risk factors: Targeting high risk individuals. Am J Cardiol 76:8a, 1995 (suppl)
5. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG: Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1:1050, 1980
6. Suzuki T Yamauchi K Matsushita T Furumichi T Furui H, Tsuzuki J Saito H: Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 14:731, 1991
7. Huffman CJ, Miller RH Lawson WE Hultin MB: Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 14:941, 1989
8. Kario K Miyata T Sakata T Matsuo T Kato H: Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb 14:265, 1994
9. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A: Factor VII-deficient substrate plasma depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: An international study. Thromb Haemost 71:38, 1994
10. Neuenschwander PF, Morrissey JH: Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity. J Biol Chem 267:14477, 1992
11. Wildgoose P Nemerson Y Hansen LL Nielsen FE Glazer S Hedner U: Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80:25, 1992
12. Morrissey JH Macik BG Neuenschwander PF Comp PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734, 1993
13. Fiore MM Neuenschwander PF Morrissey JH: The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem 269:143, 1994
14. Merrifield RB: Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol 32:221, 1969
15. 1+2. Thromb Haemost 70:253, 1993
16. Pelzer H, Schwanz A, Stuber W: Quantitative immunochemical determination of human factor VIIa in plasma with an antibody against a synthetic peptide. Thromb Haemost 65:743, 1991 (abstr)
17. Boisclair MD Lane DA Philippou H Esnouf MP Sheikh S, Hunt B Smith KJ: Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82:3350, 1993
18. Philippou H, Adami A, Lane DA, MacGregor IR, Tuddenham E, Lowe GDO, Rumley A, Ludlam CA: High purity factor IX and prothrombin complex concentrate (PCC): Pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 76:23, 1996
19. Alien CA, Muth JD, Gildersleeve N: Extraction and detergent/ lipid activation of dolichol kinase. Biochim Biophys Acta 712:33, 1982
20. Fair DS: Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 62:784, 1983
21. Meade TW, Brozovic M, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imenson JD, Thomson SG: Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study. Lancet 2:533, 1986
22. Hultin MB: Fibrinogen and factor VII as risk factors in vascular disease. Prog Thromb Hemost 10:215, 1991
23. Merlini PA Ardissino D Oltrona L Broccolino M Coppola R Mannucci PM: Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 15:1675, 1995
24. Merlini PA Bauer KA Oltrona L Ardissino D Cattaneo M Belli C Mannucci PM Rosenberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61, 1994